ELENA CIAGLIA | Curriculum
Curriculum Docente
| WORK EXPERIENCE |
| 2022 - Present | Assistant Professor of Clinical Pathology MED/05 | |
| University of Salerno, Department of Medicine, Surgery and Dentistry | ||
| ▪ Characterization of immune profile and molecular signaling in longevity models both in experimental models and in human | ||
| 2019-2021 | Research Assistant Fellow | |
| University of Salerno, Department of Medicine, Surgery and Dentistry | ||
| ▪ Cardio-immuno crosstalk and longevity immuneprofile | ||
| 2017-2019 | Post-Doc Research fellowship“Fondazione Umberto Veronesi" | |
| Fondazione Umberto Veronesi - via Solferino 19, 20121 Milano - Tel. 02 76018187 (https://www.fondazioneveronesi.it/ricerca/i-nostri-ricercatori/elena-ciaglia) | ||
| ▪ Immunesenescence studies | ||
| 2015 -2016 | Research Assistant Fellow | |
|
| University of Salerno, Department of Medicine, Surgery and Dentistry | |
|
| ▪ Novel biomarkers of Inflammatory diseases. | |
| 2011 -2014 | Post-Doc Research fellowship “Fondazione Italiana Ricerca sul Cancro" | |
| Fondazione AIRC per la Ricerca sul Cancro, Viale Isonzo 25, 20135 Milano | ||
| ▪ Anti-glioma effects of cannabinoids. | ||
| 2015 -2016 | Special Volunteer | |
| National Institutes of Health (NIH)- Laboratory of Immunoregulation at National Institutes of Allergy and Infectious Diseases-Bethesda, MD (United States) | ||
| ▪ Immunomodulatory effects of the HAART Antiretroviral therapy |
| EDUCATION AND TRAINING |
| 2019-present | Achievement of the National Scientific Habilitation (ASN 2016) as Associate Professor sc 06/A2 –Experimental medicine, pathophysiology, and clinical pathology (SSD MED/04) - | |
| Italian Ministry of Education, University and Research (MIUR). | ||
| 2006-2010 | Ph.D. Program in Molecular Oncology and Endocrinology | |
| University of Naples “Federico II” | ||
| 2004-2006 | Master degree in Medical Biotechnology | |
| University of Naples “Federico II” | ||
| ▪ Role of TLR4 in the survival of Dendritic Cells (DCs) | ||
| 2001-2004 | Bachelor’s degree in Biotechnology | |
| University of Naples “Federico II” | ||
| ▪ Analysis of T cell receptor repertoire in human pathology | ||
| ADDITIONAL INFORMATION |
|
| Last relevant publications
| 1. Ciaglia E, et al. Transfer of the Longevity associated variant of BPIFB4 gene rejuvenates immune system and vasculature by a reduction of CD38+macrophages and NAD+ decline. Cell Death Dis. 2022 13:86 ; https://doi.org/10.1038/s41419-022-04535-z IF 8,46. 2. Ciaglia E, et al. BPIFB4 circulating levels and its prognostic relevance in COVID-19. J Gerontol A Biol Sci Med Sci. 2021, Sep 13;76(10):1775-1783. doi: 10.1093/gerona/glab208 IF 6,05 3. Montella F, Lopardo V, Vecchione C, Puca AA, Ciaglia E. High TARC plasma levels confer protection to long living individuals by inducing M2 profile. Cytokine. 2021 Jan;137:155305. doi: 10.1016/j.cyto.2020.155305. IF 3,8 4. Di Pardo A*, Ciaglia E*, et al. The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease. Cell Death Dis. 2020 Jul 18;11(7):546. doi: 10.1038/s41419-020-02754-w. IF 8,46.*First Co-author. 5. Ciaglia E, et al. Circulating BPIFB4 Levels Associate With and Influence the Abundance of Reparative Monocytes and Macrophages in Long Living Individuals. Front Immunol. 2020 May 29;11:1034. doi: 10.3389/fimmu.2020.01034. IF 6,4 6. Puca AA et al., Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism" -European Heart Journal (2019) 00, 1-12 BASIC SCIENCE. doi:10.1093/eurheartj/ehz459 IF 29,9 7. Ciaglia E* et al., A bioavailability study on microbeads and nanoliposomes fabricated by dense carbon dioxide technologies using human-primary monocytes and flow cytometry assay. Int J Pharm. 2019 Oct 30;570:118686. doi: 10.1016/j.ijpharm.2019.118686. Epub 2019 Sep 9. IF 5,8 First Co-author
|
